New head of Calif. stem cell group

Richard Murphy, former head of the Salk Institute for Biological Studies, will assume the role of interim president of the California Institute for Regenerative Medicine, the agency announced yesterday. Murphy will take over for Lori Hoffman, who served as acting present since the spring, when linkurl:Zach Hall;http://www.the-scientist.com/news/display/24357/ resigned from CIRM's top position. "We are grateful that Dr. Murphy has agreed to assume this responsibility for a period up t

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Richard Murphy, former head of the Salk Institute for Biological Studies, will assume the role of interim president of the California Institute for Regenerative Medicine, the agency announced yesterday. Murphy will take over for Lori Hoffman, who served as acting present since the spring, when linkurl:Zach Hall;http://www.the-scientist.com/news/display/24357/ resigned from CIRM's top position. "We are grateful that Dr. Murphy has agreed to assume this responsibility for a period up to the beginning of March, 2008, while we complete the search and transition to a new permanent president," Robert Klein, chairman of the Independent Citizens Oversight Committee (ICOC), which governs CIRM, linkurl:said;http://www.cirm.ca.gov/press/pdf/2007/08-08-07.pdf in a statement. According to the Foundation for Taxpayer and Consumer Rights in Santa Monica, who supports stem cell research but has been a vocal critic of CIRM, Murphy will recuse himself from decisions involving institutions located in San Diego, where Salk is based. Murphy said he does not want to accept a permanent position as CIRM president, since he plans to move to the East Coast. He will receive $300,000 for the six month temporary position. What do you think about this development? Let us know, and check in tomorrow for more complete coverage in our daily news.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies